Pharma Research Products Co., Ltd (214450)
KRX
414,500.00
-1,500.00 (-0.36%)
Closed
Aug 25, 2026
Day's Range
403,500.00419,000.00
52 wk Range
255,000.00713,000.00
Financial Statements - 214450 - Pharma Research Products Co., Ltd
Revenue
536.28B▲ 53.2%
Net Income
168.25B▲ 89.2%Net Margin 31.4%
EBITDA
243.27B▲ 52.0%
Free Cash Flow
147.38B▲ 48.3%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 536.28B | 350.11B | 261.01B | 194.75B | 154.08B | 108.74B |
| Cost of Goods | 125.07B | 98.87B | 70.75B | 53.24B | 45.75B | 35.84B |
| Gross Profit | 411.21B | 251.23B | 190.25B | 141.51B | 108.33B | 72.89B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 214.39B | 126.05B | 92.25B | 65.91B | 52.48B | 33.42B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 216.51B | 115.81B | 100.70B | 54.04B | 56.03B | 39.53B |
| Income Tax | 48.25B | 26.86B | 23.43B | 10.61B | 9.20B | 7.08B |
| Net Income | 168.25B | 88.94B | 77.26B | 43.43B | 46.82B | 32.45B |
| EPS Basic | 15.89K | 8.94K | 7.57K | 4.06K | 4.71K | 3.44K |
| EPS Diluted | 14.93K | 8.94K | 7.50K | 4.06K | 4.71K | 3.44K |
| Basic Shares Outstanding | 10.38M | 10.29M | 10.11M | 9.97M | 9.89M | 9.50M |
| Diluted Shares Outstanding | 10.38M | 10.29M | 10.11M | 9.97M | 9.89M | 9.50M |
| Ebit | 226.90B | 120.44B | 103.69B | 57.87B | 57.34B | 41.32B |
| Ebitda | 243.27B | 160.07B | 111.71B | 79.38B | 66.93B | 52.05B |
| Net Income Continuous Operations | 168.25B | 88.94B | 77.26B | 43.43B | 46.82B | 32.45B |
| Minority Interests | -3.13B | 3.10B | -713.43M | -2.85B | -134.98M | 322.10M |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
